Clinical trial · no report yet · Phase 3
LASER301
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
- NCT04248829 ↗
- Completed
- Yuhan Corporation
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Lazertinib 240 mg/160 mg; Gefitinib 250 mg; Lazertinib-matching placebo 240 mg/160 mg; Gefitinib-matching placebo 250 mg
- Arms
- Lazertinib + Gefitinib-matching placebo · Experimental
- Gefitinib + Lazertinib-matching placebo · Active comparator
- Enrollment
- 393
- Primary outcomes
- Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment
- Sponsor
- Yuhan Corporation
- Start
- Feb 13, 2020
- Primary completion
- Jul 29, 2022
- Results posted
- Yes
- Registry record
- NCT04248829 · updated Jun 29, 2026
Publications
linked from the registry- Soo RA, Cho BC, Kim JH, Ahn MJ, Lee KH, Zimina A, Orlov S, Bondarenko I, Lee YG, Lim YN, Lee SS, Lee KH, Pang YK, Fong CH, Kang JH, Lim CS, Danchaivijitr P, Kilickap S, Yang JC, Arslan C, Lee H, Park SN, Cicin I. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis. J Thorac Oncol. 2023 Dec;18(12):1756-1766. doi: 10.1016/j.jtho.2023.08.017. Epub 2023 Oct 22. PubMed 37865896
- Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. PubMed 37379502